Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07899895 Phase 1 in healthy volunteers
NCT06137729Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing PF-07899895 with Placebo (2 arms). Primary endpoints: Adverse Events, Laboratory Abnormalities and 3 more. Started Nov 2023; status: terminated.
02
Drugs
PF-07899895
Beyond the preview
Go deeper on NCT06137729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137729.